Rifampicin is one of 199 small molecule programs targeting Tics. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
268 competitors in Colorectal Cancer
Camptosar
Keytruda
Fudr
Tyvyt
Platinol
Botensilimab
Zanzalintinib
TAS 102
Cadonilimab
Serplulimab
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details